ArticleBone marrow transplantation2026

Low-dose post-transplant cyclophosphamide in combination with low-dose alemtuzumab for graft-versus-host-disease prevention in mismatched unrelated allogeneic stem cell transplantation is associated with improved outcomes and reduced toxicity.

Ioanna Lazana et al.PubMed ↗Publisher ↗

No numbers read from the abstract.